ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Clinical trials for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to stop stomach Cancer's return after surgery
Disease control Recruiting nowThis study is testing whether adding a drug called sintilimab to standard chemotherapy helps prevent cancer from coming back after surgery for stage III stomach or upper stomach cancer. About 70 people who have had surgery will receive the drug combination for up to 16 treatment …
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Scientists test Triple-Threat treatment to shrink tumors before surgery
Disease control Recruiting nowThis study is testing a new combination treatment for people with stage III stomach or gastroesophageal junction cancer. The goal is to see if giving immunotherapy (Serplulimab), an immune-boosting drug (thymalfasin), and standard chemotherapy (SOX) before surgery can shrink tumo…
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zekuan Xu • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New combo therapy tested to boost stomach cancer fight before surgery
Disease control Recruiting nowThis early-stage trial is testing whether combining a newer immunotherapy drug (tislelizumab) with standard chemotherapy (FLOT) is safe and tolerable when given before surgery for certain stomach and esophagus cancers. The goal is to see if giving more chemotherapy before surgery…
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC